{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:30:46Z","timestamp":1794011446717,"version":"4.8.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ligand-induced receptor dimerization or oligomerization is a widespread mechanism for ensuring communication specificity, safeguarding receptor activation, and facilitating amplification of signal transduction across the cellular membrane. However, cell-surface antigen-induced multimerization (dubbed AIM herein) has not yet been consciously leveraged in chimeric antigen receptor (CAR) engineering for enriching T cell-based therapies. We co-developed ciltacabtagene autoleucel (cilta-cel), whose CAR incorporates two B-cell maturation antigen (BCMA)-targeted nanobodies in tandem, for treating multiple myeloma. Here we elucidated a structural and functional model in which BCMA-induced cilta-cel CAR multimerization amplifies myeloma-targeted T cell-mediated cytotoxicity. Crystallographic analysis of BCMA\u2013nanobody complexes revealed atomic details of antigen\u2013antibody hetero-multimerization whilst analytical ultracentrifugation and small-angle X-ray scattering characterized interdependent BCMA apposition and CAR juxtaposition in solution. BCMA-induced nanobody CAR multimerization enhanced cytotoxicity, alongside elevated immune synapse formation and cytotoxicity-mediating cytokine release, towards myeloma-derived cells. Our results provide a framework for contemplating the AIM approach in designing next-generation CARs.<\/jats:p>","DOI":"10.1038\/s41392-023-01686-z","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T19:02:31Z","timestamp":1701975751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity"],"prefix":"10.1038","volume":"8","author":[{"given":"Yan","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3443-9815","authenticated-orcid":false,"given":"Xiu-Na","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8268-5343","authenticated-orcid":false,"given":"Shuang-Shuang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Zhu","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2186-8031","authenticated-orcid":false,"given":"Kai-Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Chen","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Xiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5322-8621","authenticated-orcid":false,"given":"Cheng-Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Qing","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hu","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3789-1284","authenticated-orcid":false,"given":"Sai-Juan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"key":"1686_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0092-8674(95)90404-2","volume":"80","author":"CH Heldin","year":"1995","unstructured":"Heldin, C. H. Dimerization of cell surface receptors in signal transduction. Cell 80, 213\u2013223 (1995).","journal-title":"Cell"},{"key":"1686_CR2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0092-8674(00)00114-8","volume":"103","author":"J Schlessinger","year":"2000","unstructured":"Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 103, 211\u2013225 (2000).","journal-title":"Cell"},{"key":"1686_CR3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0092-8674(01)00237-9","volume":"104","author":"RM Locksley","year":"2001","unstructured":"Locksley, R. M., Killeen, N. & Lenardo, M. J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104, 487\u2013501 (2001).","journal-title":"Cell"},{"key":"1686_CR4","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41586-019-1537-0","volume":"573","author":"D Dong","year":"2019","unstructured":"Dong, D. et al. Structural basis of assembly of the human T cell receptor-CD3 complex. Nature 573, 546\u2013552 (2019).","journal-title":"Nature"},{"key":"1686_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med 379, 64\u201373 (2018).","journal-title":"N. Engl. J. Med"},{"key":"1686_CR6","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","volume":"168","author":"WA Lim","year":"2017","unstructured":"Lim, W. A. & June, C. H. The principles of engineering immune cells to treat cancer. Cell 168, 724\u2013740 (2017).","journal-title":"Cell"},{"key":"1686_CR7","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H., O\u2019Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361\u20131365 (2018).","journal-title":"Science"},{"key":"1686_CR8","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med 21, 581\u2013590 (2015).","journal-title":"Nat. Med"},{"key":"1686_CR9","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41591-021-01326-5","volume":"27","author":"N Singh","year":"2021","unstructured":"Singh, N. et al. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nat. Med 27, 842\u2013850 (2021).","journal-title":"Nat. Med"},{"key":"1686_CR10","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/0092-8674(91)90314-O","volume":"64","author":"BA Irving","year":"1991","unstructured":"Irving, B. A. & Weiss, A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64, 891\u2013901 (1991).","journal-title":"Cell"},{"key":"1686_CR11","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/0092-8674(91)90327-U","volume":"64","author":"C Romeo","year":"1991","unstructured":"Romeo, C. & Seed, B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 64, 1037\u20131046 (1991).","journal-title":"Cell"},{"key":"1686_CR12","doi-asserted-by":"publisher","first-page":"8905","DOI":"10.1073\/pnas.88.20.8905","volume":"88","author":"F Letourneur","year":"1991","unstructured":"Letourneur, F. & Klausner, R. D. T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins. Proc. Natl Acad. Sci. USA 88, 8905\u20138909 (1991).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1686_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nchembio.2565","volume":"14","author":"ZL Chang","year":"2018","unstructured":"Chang, Z. L. et al. Rewiring T-cell responses to soluble factors with chimeric antigen receptors. Nat. Chem. Biol. 14, 317\u2013324 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"1686_CR14","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/79802","volume":"1","author":"G Yu","year":"2000","unstructured":"Yu, G. et al. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat. Immunol. 1, 252\u2013256 (2000).","journal-title":"Nat. Immunol."},{"key":"1686_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","volume":"199","author":"BP O\u2019Connor","year":"2004","unstructured":"O\u2019Connor, B. P. et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199, 91\u201398 (2004).","journal-title":"J. Exp. Med."},{"key":"1686_CR16","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","volume":"103","author":"AJ Novak","year":"2004","unstructured":"Novak, A. J. et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103, 689\u2013694 (2004).","journal-title":"Blood"},{"key":"1686_CR17","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","volume":"127","author":"YT Tai","year":"2016","unstructured":"Tai, Y. T. et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood 127, 3225\u20133236 (2016).","journal-title":"Blood"},{"key":"1686_CR18","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.3892\/ol.2017.6528","volume":"14","author":"J Pan","year":"2017","unstructured":"Pan, J. et al. Characteristics of BAFF and APRIL factor expression in multiple myeloma and clinical significance. Oncol. Lett. 14, 2657\u20132662 (2017).","journal-title":"Oncol. Lett."},{"key":"1686_CR19","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah, N., Chari, A., Scott, E., Mezzi, K. & Usmani, S. Z. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 34, 985\u20131005 (2020).","journal-title":"Leukemia"},{"key":"1686_CR20","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.3390\/jcm10184088","volume":"10","author":"M Kleber","year":"2021","unstructured":"Kleber, M., Ntanasis-Stathopoulos, I. & Terpos, E. BCMA in multiple myeloma-a promising key to therapy. J. Clin. Med. 10, 4088 (2021).","journal-title":"J. Clin. Med."},{"key":"1686_CR21","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan, A. J. et al. Diagnosis and management of multiple myeloma a review. Jama-J. Am. Med. Assoc. 327, 464\u2013477 (2022).","journal-title":"Jama-J. Am. Med. Assoc."},{"key":"1686_CR22","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med"},{"key":"1686_CR23","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","volume":"116","author":"J Xu","year":"2019","unstructured":"Xu, J. et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma. Proc. Natl Acad. Sci. USA 116, 9543\u20139551 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1686_CR24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel, J. et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N. Engl. J. Med. 389, 335\u2013347 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1686_CR25","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1182\/blood.2020008936","volume":"137","author":"D Wang","year":"2021","unstructured":"Wang, D. et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma. Blood 137, 2890\u20132901 (2021).","journal-title":"Blood"},{"key":"1686_CR26","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari, A. et al. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody. N. Engl. J. Med 387, 2232\u20132244 (2022).","journal-title":"N. Engl. J. Med"},{"key":"1686_CR27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"WH Zhao","year":"2018","unstructured":"Zhao, W. H. et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J. Hematol. Oncol. 11, 141 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"1686_CR28","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"1686_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","volume":"15","author":"WH Zhao","year":"2022","unstructured":"Zhao, W. H. et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J. Hematol. Oncol. 15, 86 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"1686_CR30","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.22.00690","volume":"41","author":"JQ Mi","year":"2022","unstructured":"Mi, J. Q. et al. Phase II, Open-label study of ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen Receptor-T-Cell therapy, in Chinese patients with relapsed\/refractory multiple myeloma (CARTIFAN-1). J. Clin. Oncol. 41, 1275\u20131284 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1686_CR31","doi-asserted-by":"publisher","first-page":"16727","DOI":"10.1074\/jbc.M312316200","volume":"279","author":"DR Patel","year":"2004","unstructured":"Patel, D. R. et al. Engineering an APRIL-specific B cell maturation antigen. J. Biol. Chem. 279, 16727\u201316735 (2004).","journal-title":"J. Biol. Chem."},{"key":"1686_CR32","doi-asserted-by":"publisher","first-page":"7218","DOI":"10.1074\/jbc.M411714200","volume":"280","author":"SG Hymowitz","year":"2005","unstructured":"Hymowitz, S. G. et al. Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding. J. Biol. Chem. 280, 7218\u20137227 (2005).","journal-title":"J. Biol. Chem."},{"key":"1686_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature01543","volume":"423","author":"Y Liu","year":"2003","unstructured":"Liu, Y. et al. Ligand-receptor binding revealed by the TNF family member TALL-1. Nature 423, 49\u201356 (2003).","journal-title":"Nature"},{"key":"1686_CR34","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.molonc.2015.03.010","volume":"9","author":"F Oden","year":"2015","unstructured":"Oden, F. et al. Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma. Mol. Oncol. 9, 1348\u20131358 (2015).","journal-title":"Mol. Oncol."},{"key":"1686_CR35","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.3389\/fimmu.2018.03037","volume":"9","author":"SC Clarke","year":"2018","unstructured":"Clarke, S. C. et al. Multispecific antibody development platform based on human heavy chain antibodies. Front Immunol. 9, 3037 (2018).","journal-title":"Front Immunol."},{"key":"1686_CR36","doi-asserted-by":"publisher","first-page":"26607","DOI":"10.1016\/S0021-9258(19)74355-5","volume":"268","author":"S Hennecke","year":"1993","unstructured":"Hennecke, S. & Cosson, P. Role of transmembrane domains in assembly and intracellular-transport of the Cd8 molecule. J. Biol. Chem. 268, 26607\u201326612 (1993).","journal-title":"J. Biol. Chem."},{"key":"1686_CR37","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.ymthe.2017.06.003","volume":"25","author":"M Mukherjee","year":"2017","unstructured":"Mukherjee, M., Mace, E. M., Carisey, A. F., Ahmed, N. & Orange, J. S. Quantitative imaging approaches to study the CAR immunological synapse. Mol. Ther. 25, 1757\u20131768 (2017).","journal-title":"Mol. Ther."},{"key":"1686_CR38","doi-asserted-by":"publisher","first-page":"102931","DOI":"10.1016\/j.ebiom.2020.102931","volume":"58","author":"J Jayaraman","year":"2020","unstructured":"Jayaraman, J. et al. CAR-T design: elements and their synergistic function. EBioMedicine 58, 102931 (2020).","journal-title":"EBioMedicine"},{"key":"1686_CR39","doi-asserted-by":"publisher","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","volume":"11","author":"EL Smith","year":"2019","unstructured":"Smith, E. L. et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci. Transl. Med. 11, eaau7746 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1686_CR40","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody, S. et al. GPRC5D-targeted CAR T cells for myeloma. N. Engl. J. Med 387, 1196\u20131206 (2022).","journal-title":"N. Engl. J. Med"},{"key":"1686_CR41","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0006-3495(00)76713-0","volume":"78","author":"P Schuck","year":"2000","unstructured":"Schuck, P. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. Biophys. J. 78, 1606\u20131619 (2000).","journal-title":"Biophys. J."},{"key":"1686_CR42","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1107\/S0907444909047337","volume":"66","author":"W Kabsch","year":"2010","unstructured":"Kabsch, W. XDS. Acta Crystallogr D. Biol. Crystallogr 66, 125\u2013132 (2010).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"1686_CR43","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl Crystallogr 40, 658\u2013674 (2007).","journal-title":"J. Appl Crystallogr"},{"key":"1686_CR44","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D. Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"1686_CR45","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D. Biol. Crystallogr. 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"1686_CR46","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1107\/S0021889809023863","volume":"42","author":"SS Nielsen","year":"2009","unstructured":"Nielsen, S. S. et al. BioXTAS RAW, a software program for high-throughput automated small-angle X-ray scattering data reduction and preliminary analysis. J. Appl. Crystallogr. 42, 959\u2013964 (2009).","journal-title":"J. Appl. Crystallogr."},{"key":"1686_CR47","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1107\/S0021889812007662","volume":"45","author":"MV Petoukhov","year":"2012","unstructured":"Petoukhov, M. V. et al. New developments in the ATSAS program package for small-angle scattering data analysis. J. Appl. Crystallogr. 45, 342\u2013350 (2012).","journal-title":"J. Appl. Crystallogr."},{"key":"1686_CR48","first-page":"e55345","volume":"143","author":"G Wabnitz","year":"2019","unstructured":"Wabnitz, G., Kirchgessner, H. & Samstag, Y. Qualitative and quantitative analysis of the immune synapse in the human system using imaging flow cytometry. J. Vis. Exp. 143, e55345 (2019).","journal-title":"J. Vis. Exp."},{"key":"1686_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ymeth.2016.09.013","volume":"112","author":"E Balta","year":"2017","unstructured":"Balta, E. et al. Qualitative and quantitative analysis of PMN\/T-cell interactions by InFlow and super-resolution microscopy. Methods 112, 25\u201338 (2017).","journal-title":"Methods"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01686-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01686-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01686-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T19:02:36Z","timestamp":1701975756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01686-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1686"],"URL":"https:\/\/doi.org\/10.1038\/s41392-023-01686-z","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]},"assertion":[{"value":"27 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"X.-H.F. has financial interests in ciltacabtagene autoleucel. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"445"}}